

LanthaScreen[®] Terbium Assay Setup Guide on the BMG LABTECH POLARstar Omega Microplate Readers

NOTE: The BMG LABTECH POLARstar Omega Microplate Reader was tested for compatibility with Invitrogen's LanthaScreen[®] Terbium-based TR-FRET Assay using the LanthaScreen[®] Fluorescein-Poly GT (PV3610) and Tb-PY20 antibody (PV3552) against JAK2 JH1/JH2 and JAK2 JH1/JH2 V617F kinases. The following document is intended to demonstrate setup of this instrument and provide representative data. For more detailed information and technical support of Invitrogen assays please call 1-800-955-6288, select option "3", then extension 40266. For more detailed information and technical support of BMG LABTECH instruments or software, please contact BMG LABTECH at 1-877-264-5227 or www.bmglabtech.com.

A. Recommended Optics

	wavelength (nm)	BMG LABTECH Filters
Excitation	337	*contact BMG LABTECH
Emission 1	520-10	*contact BMG LABTECH
Emission 2	490-10	*contact BMG LABTECH
TR-FRET Optic Module Height Setting "11"	N/A	N/A

B. Instrument Setup

1. Make certain plate reader is turned on, and open up Omega Control software on computer. Insert plate into plate reader.



2. When Omega Control software opens, if you do not have a pre-existing protocol for LanthaScreen[®], select "Test Protocol" from the Test Setup menu bar at the top of the window.





Version No.:

6 Jan 10

3. At this point, a new screen will open (below). Click on the "Show all test protocols" or "Time Resolved Fluorescence" button on the left side of the screen, then select "New" from the tabs at the bottom.





LanthaScreen[®] Compatible Microplate Reader Documentation

Setup Guide on the BMGLABTECH POLARstar Omega Microplate Reader

4. A new window will pop up. Select "Time-Resolved Fluorescence" and "Endpoint" and then select "OK".



5. A new Protocol window will open automatically. Enter a test name and select plate type. Because LanthaScreen[®] is a Time-Resolved FRET assay, set the "Integration: Start" and "Integration: Time" to 100 and 200 µs, respectively, as shown. When finished, enter a 2 in the "No. of multichromatics" box and then click on the arrow next to it.

Version No.:

6 Jan 10

6. Select your donor and acceptor filters in the drop-down windows provided. Make certain"Integr. start" and "Integr. time" are set to 100 and 200 μs, respectively, for both channels. When finished, select the "Layout" tab.

🖲 OMEGA_Lan	thaScreen_Jun09 - Microsoft	Word						J ×
Eile Edit ⊻ie	ew Insert Format Tools Tab	le <u>W</u> indow <u>H</u> elp				Туре а	a question for help	- ×
		🚿 n + a + 🍓 🖪		¶ 100% - 🤶) -			
Normal + Le	Ω Omega							
i manage re	Setup Test Setup Measure	Results Help	T					
Copy	🗩 🗩 🕇 海 🗄	est duration 500 +	🛛 🖓 🚺	1.8 🔍 I		-		-
Drag a column t	Time Resolved Fluorescenc	e - Endpoint						
State Signed Te	Basic Parameters Layout Cond	entrations / Volumes / Shaking	Multichromatic				rotocol Comment	
EL	Number Excitation filter	Emission filter	Gain (04095)	Integr. start (121510 μs)	Integr. time (101510 μs)			
AL	1 Lantha 💌	490-10 💌	2500	100	200			
AL	2 Lantha 💌	520-10 💌	2500	100	200			
A	3 🗾	_	0	400	400			
W	4 🗾	_	0	400	400			
PN	5 💌		0	400	400			
MA NO	6 🗾		0	400	400			
Pr	7 🗾	_	0	400	400			
DI	8 🗾	-	0	400	400			
SF								
04							uality test based (
04	1						uality test based (
	Cheek limine							-
								1
	Optic: Huorescence	User: USER	Path: C:(Program	n Hiles(BMG(Omega(U	iseri,Data Re	аду		*
Number of available test runs: 19							_	
🐉 start	🗁 OMEGA templates 🛛 🛗	lime Resolved F 🚺 Om	ega - Control 🛛 🔶 Bi	MG LABTECH	MEGA_Lantha	/ 🕫 🛛 🗘 🌾	😄 🖏 🔜 🛄 113	8 PM

7. Select the wells you wish to read. Note in this step you can select to designate blanks, positive controls, etc. but for this case we marked all wells "Sample" and calculations were performed manually. When finished, select "OK".

8. You will return to the main window. From the drop-down menu at the top, select "Measure" and "Measure" again to read plate.

9. A new window will appear allowing you to select which of your test protocols you wish to run. Select the protocol you created for LanthaScreen[®], and then press "OK".

Page 10 of 15

Setup Guide on the BMGLABTECH POLARstar Omega Microplate Reader

10. A new window will appear. Place your plate in the reader, and select a well to use for adjusting gain. When finished, click on the "Start Adjustment" tab. In this case we highlighted the 490 channel and selected a low-FRET well to adjust the donor gain, and then highlighted the 520 channel and selected a high-FRET well to optimize the acceptor gain. When both channels have been optimized, select the "Start Measurement" tab to measure plate.

11. When Omega is done reading, you can collect your data under the "Results" tab. This will automatically redirect you to the MARS data analysis software. Select your run of interest from the list to open.

Version No.:

6 Jan 10

LanthaScreen[®] Kinase Assay using JAK2 JH1/JH2 and JAK2 JH1/JH2 V617F С.

NOTE: The following is a sample titration assay performed for demonstration purposes. The instrument settings above would be sufficient for any LanthaScreen[®] assay, the information below is provided as representative data only and the following section is an explanation of what was done. We recommend all first-time users begin by following the provided assayspecific protocols and/or validation packets, and include proper controls. This assay was run at ATP Km_{app} and a kinase concentration producing approximately 70-80% of maximal phosphorylation. ATP and kinase concentrations should be optimized for each kinase by the actual user and titrations/plate layout may be optimized as well. For more information on setting up assays, visit www.invtrogen.com/lanthascreenkinase.

1. Prepare initial 100X serial dilution curves in rows A, E, I, and M of a 384-well plate (Figure 1): Dilute Staurosporine, JAK2 Inhibitor 2, JAK3 Inhibitor, and AG-490 to a 100X initial concentration (100uM) in 100% DMSO. Prepare a set of 1:1 serial dilutions from the initial concentration in a 384-well plate, starting with 80 µl in Column 1 and 40 µl DMSO in wells 2-20. Add 40 µl from well 1 to well 2, and then mix well 2, and take 40 µl from well 2 and add to well 3, mix, and so on.

Figure 1: Schematic of initial compound dilution. Staurosporine, JAK2 Inhibitor II, JAK3 Inhibitor, and AG-490 were all titrated from a 100 µM starting concentration in the initial dilution series by preparing a 1:1 dilution curve in DMSO. A secondary dilution to 4X was then prepared in the rows below the initial dilution curve (lighter gray) using kinase buffer.

2. The 100X serial dilution set is then diluted to a 4X working concentration in Kinase Buffer (PV3189, 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA) in the row below by adding 2 µl of diluted inhibitor from the well above to 48 µl of kinase buffer. This will produce a final serial dilution starting at 4 μ M, which will then produce a final assay concentration starting at 1 μ M.

- 3. Begin to prepare an assay plate: Add 2.5 µl of the compound dilutions per well into a low volume NBS, 384-well plate (Corning Cat. # 3676), in quadruplicate so rows A-D are staurosporine replicates, E-H are JAK2 Inhibitor 2 replicates, etc.
- Add 2.5 µl of kinase buffer alone to rows 21 and 22 (0% inhibition no compound control), 23 (0% phosphorylation control, no kinase added) and 24 (Phosphopeptide 100% phosphorylation positive control).
- 5. Add 5 µl of the 2X Peptide/Kinase Mixture (800 nM Fluorescein-Poly GT peptide, PV3610, 222 ng/ml JAK2 JH1/JH2 or 270 ng/ml JAK2 JH1/JH2 V617F, determined experimentally as outlined above) to Columns 1-22. DO NOT ADD TO COLUMN 23 OR 24. Add 5 µl of 800 nM substrate alone without kinase to Column 23, rows A-L (0% phosphorylation control) and 5 µl of 800 nM phosphopeptide control substrate to Column 24, rows A-L (100% phosphorylation control). Add 5µl kinase buffer alone to the remaining 8 wells (Columns 23 and 24, rows M-P) as a buffer-only reference.
- 6. Add 2.5 μl of 4X ATP Solution (20 μM) per well to all Columns to start reaction.
- 7. Shake assay plate on a plate shaker for 30 seconds.
- 8. Incubate assay plate for 60 minutes at room temperature.
- Add 10 μl per well of 20 mM EDTA, 2 nM TB-PY20 antibody (PV3552) mix diluted in TR-FRET Dilution Buffer (PV3574) per well to stop kinase reaction. Do not add to Rows M-P,Columns 23 and 24 (buffer controls only), instead replace with 10 μl TR-FRET Dilution Buffer supplemented with EDTA only.
- 10. Shake plate again on a plate shaker for 30 seconds.
- 11. Incubate for 30 minutes at room temperature.
- 12. Read and analyze as directed in the protocol.

LanthaScreen[®] Compatible Microplate Reader Documentation Version No.: 6 Jan 10

Page 14 of 15

Setup Guide on the BMGLABTECH POLARstar Omega Microplate Reader

Figure 2: Assay Plate Schematic. Compound titrations shown in Columns 1-20, Columns 21 and 22 prepared without any inhibitor as kinase activity controls, Column 23 prepared with no kinase (0% phosphorylation) and Column 24 prepared using phosphopeptide control (100% phosphorylation). Note 8 wells in gray in bottom right, which were prepared with out any inhibitor, substrates, or antibody as buffer controls.

ė invitrogen	LanthaScreen [®] Compatible Microplate Reader Documentation	Version No.: 6 Jan 10	Page 15 of 15		
j	Setup Guide on the BMGI ABTECH POI ARstar Omega Microplate Reader				

D. Results:

Note: The results shown are meant as representative data only. The actual ratio values obtained may vary from instrument to instrument. Values are dependent on multiple factors including but not limited to the specific setup of each instrument, plate type and assay target.

Figure 3: LanthaScreen[®] Assay. LanthaScreen[®] assay performed on the BMG LABTECH POLARstar Omega.